Dr. Mesa on Guideline Updates in Polycythemia Vera and Essential Thrombocythemia

Ruben Mesa, MD
Published: Sunday, Oct 08, 2017



Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

Diseases like polycythemia vera and essential thrombocythemia are unique, says Mesa, as they are malignancies, but a lot of patients have very long survival. However, some can progress.

Mesa states that the primary goal of the guidelines is the avoidance of thrombosis and bleeding in a risk-based fashion.


Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

Diseases like polycythemia vera and essential thrombocythemia are unique, says Mesa, as they are malignancies, but a lot of patients have very long survival. However, some can progress.

Mesa states that the primary goal of the guidelines is the avoidance of thrombosis and bleeding in a risk-based fashion.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x